189 related articles for article (PubMed ID: 35195371)
21. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
[TBL] [Abstract][Full Text] [Related]
22. Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1.
Hashizume M; Takashima A; Ono C; Okamoto T; Iwasaki M
Antiviral Res; 2023 Jan; 209():105481. PubMed ID: 36481388
[TBL] [Abstract][Full Text] [Related]
23. Comparison of SARS-CoV-2 Receptors Expression in Primary Endothelial Cells and Retinoic Acid-Differentiated Human Neuronal Cells.
Benedetti F; Silvestri G; Mavian C; Weichseldorfer M; Munawwar A; Cash MN; Dulcey M; Vittor AY; Ciccozzi M; Salemi M; Latinovic OS; Zella D
Viruses; 2021 Oct; 13(11):. PubMed ID: 34834998
[TBL] [Abstract][Full Text] [Related]
24. Semaphorin-3a, neuropilin-1 and plexin-A1 in prosthetic-particle induced bone loss.
Saad S; Dharmapatni AASSK; Crotti TN; Cantley MD; Algate K; Findlay DM; Atkins GJ; Haynes DR
Acta Biomater; 2016 Jan; 30():311-318. PubMed ID: 26602825
[TBL] [Abstract][Full Text] [Related]
25. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
26. Discovery of natural products to block SARS-CoV-2 S-protein interaction with Neuropilin-1 receptor: A molecular dynamics simulation approach.
Alshawaf E; Hammad MM; Marafie SK; Ali H; Al-Mulla F; Abubaker J; Mohammad A
Microb Pathog; 2022 Sep; 170():105701. PubMed ID: 35963279
[TBL] [Abstract][Full Text] [Related]
27. Osteoclast-mediated bone loss observed in a COVID-19 mouse model.
Awosanya OD; Dalloul CE; Blosser RJ; Dadwal UC; Carozza M; Boschen K; Klemsz MJ; Johnston NA; Bruzzaniti A; Robinson CM; Srour EF; Kacena MA
Bone; 2022 Jan; 154():116227. PubMed ID: 34607050
[TBL] [Abstract][Full Text] [Related]
28. Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice.
Liu X; Zaid A; Freitas JR; McMillan NA; Mahalingam S; Taylor A
mBio; 2021 Apr; 12(2):. PubMed ID: 33879586
[TBL] [Abstract][Full Text] [Related]
29. Abrogation of SARS-CoV-2 interaction with host (NRP1) neuropilin-1 receptor through high-affinity marine natural compounds to curtail the infectivity: A structural-dynamics data.
Humayun F; Khan A; Ahmad S; Yuchen W; Wei G; Nizam-Uddin N; Hussain Z; Khan W; Zaman N; Rizwan M; Waseem M; Wei DQ
Comput Biol Med; 2022 Feb; 141():104714. PubMed ID: 34772509
[TBL] [Abstract][Full Text] [Related]
30. Neuropilin-1: A feasible link between liver pathologies and COVID-19.
Benedicto A; García-Kamiruaga I; Arteta B
World J Gastroenterol; 2021 Jun; 27(24):3516-3529. PubMed ID: 34239266
[TBL] [Abstract][Full Text] [Related]
31. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
32. Replication Kinetics, Cell Tropism, and Associated Immune Responses in SARS-CoV-2- and H5N1 Virus-Infected Human Induced Pluripotent Stem Cell-Derived Neural Models.
Bauer L; Lendemeijer B; Leijten L; Embregts CWE; Rockx B; Kushner SA; de Vrij FMS; van Riel D
mSphere; 2021 Jun; 6(3):e0027021. PubMed ID: 34160239
[TBL] [Abstract][Full Text] [Related]
33. Molecular basis of the new COVID-19 target neuropilin-1 in complex with SARS-CoV-2 S1 C-end rule peptide and small-molecule antagonists.
Klaewkla M; Charoenwongpaiboon T; Mahalapbutr P
J Mol Liq; 2021 Aug; 335():116537. PubMed ID: 34031621
[TBL] [Abstract][Full Text] [Related]
34. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus.
Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J
J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775
[TBL] [Abstract][Full Text] [Related]
35. The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies.
Zalpoor H; Akbari A; Samei A; Forghaniesfidvajani R; Kamali M; Afzalnia A; Manshouri S; Heidari F; Pornour M; Khoshmirsafa M; Aazami H; Seif F
Cell Mol Biol Lett; 2022 Feb; 27(1):10. PubMed ID: 35109786
[TBL] [Abstract][Full Text] [Related]
36. Neuropilin-1 in the pathogenesis of preeclampsia, HIV-1, and SARS-CoV-2 infection: A review.
Naidoo N; Moodley J; Khaliq OP; Naicker T
Virus Res; 2022 Oct; 319():198880. PubMed ID: 35905790
[TBL] [Abstract][Full Text] [Related]
37. A Comprehensive Analysis of NRP1 in Malignancies Provide Therapeutic Implication for Treating Cancer Patients Infected with SARS-CoV-2.
Chen S; Zhang L; Song Y; Xie K; Wang Y; Liang Y
Biochem Genet; 2023 Nov; ():. PubMed ID: 37938510
[TBL] [Abstract][Full Text] [Related]
38. Host-Cell Surface Binding Targets in SARS-CoV-2 for Drug Design.
Maleksabet H; Rezaee E; Tabatabai SA
Curr Pharm Des; 2022; 28(45):3583-3591. PubMed ID: 36420875
[TBL] [Abstract][Full Text] [Related]
39. A New Butyrate Releaser Exerts a Protective Action against SARS-CoV-2 Infection in Human Intestine.
Paparo L; Maglio MA; Cortese M; Bruno C; Capasso M; Punzo E; Ferrucci V; Lasorsa VA; Viscardi M; Fusco G; Cerino P; Romano A; Troncone R; Zollo M
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164139
[TBL] [Abstract][Full Text] [Related]
40. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
